Src
Src is a non-receptor tyrosine kinase that plays a critical role in the regulation of cellular processes, including proliferation, differentiation, and survival. It is a member of the Src family kinases (SFKs), which are involved in the signaling pathways of various cellular receptors.
Structure[edit]
Src is composed of several domains that contribute to its function:
- SH3 domain: This domain binds to proline-rich sequences and is involved in protein-protein interactions.
- SH2 domain: This domain binds to phosphorylated tyrosine residues, allowing Src to interact with other phosphorylated proteins.
- Kinase domain: The catalytic domain responsible for the transfer of a phosphate group from ATP to a tyrosine residue on a substrate protein.
- Regulatory tail: The C-terminal tail contains a tyrosine residue that, when phosphorylated, inhibits Src activity.
Function[edit]
Src is involved in the regulation of several cellular processes:
- Cell growth and division: Src promotes cell cycle progression by phosphorylating key proteins involved in the cell cycle.
- Cell adhesion and migration: Src modulates the dynamics of the cytoskeleton and cell adhesion molecules, influencing cell movement.
- Signal transduction: Src is activated by various cell surface receptors, including growth factor receptors, integrins, and G-protein coupled receptors.
Regulation[edit]
Src activity is tightly regulated by phosphorylation:
- Activation: Dephosphorylation of the C-terminal tyrosine residue (Tyr527) leads to Src activation.
- Inhibition: Phosphorylation of Tyr527 by C-terminal Src kinase (Csk) inhibits Src activity.
Clinical Significance[edit]
Src has been implicated in several diseases, particularly cancer:
- Oncogenesis: Overexpression or constitutive activation of Src is associated with the development of various cancers, including breast cancer, colon cancer, and lung cancer.
- Therapeutic target: Src inhibitors, such as dasatinib, are used in the treatment of certain cancers.
Research[edit]
Ongoing research is focused on understanding the precise mechanisms by which Src contributes to cancer progression and identifying novel therapeutic strategies to target Src in cancer.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
